We previously discovered the STAT3 inhibitor YHO-1701, which exhibited a multistep regulation in the STAT3 signaling pathway by blocking the dimerization of STAT3 and demonstrated a strong antiproliferative effect and combination effect using the multikinase inhibitor sorafenib in cancer cell lines and in a human oral carcinoma SAS tumor xenograft model8. This evidence concerns the gene STAT3 and lip and oral cavity carcinoma.